CY1122761T1 - Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων - Google Patents
Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντωνInfo
- Publication number
- CY1122761T1 CY1122761T1 CY20201100220T CY201100220T CY1122761T1 CY 1122761 T1 CY1122761 T1 CY 1122761T1 CY 20201100220 T CY20201100220 T CY 20201100220T CY 201100220 T CY201100220 T CY 201100220T CY 1122761 T1 CY1122761 T1 CY 1122761T1
- Authority
- CY
- Cyprus
- Prior art keywords
- modulators
- therapeutic agents
- pharmacokinetic properties
- compounds
- administration
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει μία ένωση Τύπου IV,ή ένα φαρμακευτικώς αποδεκτό άλας, διαλύτωμα, και/ή εστέρα αυτής, συνθέσεις που περιέχουν αυτές τις ενώσεις, θεραπευτικές μεθόδους που περιλαμβάνουν τη χορήγηση αυτών των ενώσεων και θεραπευτικές μεθόδους που περιλαμβάνουν τη χορήγηση αυτών των ενώσεων με τουλάχιστον έναν επιπρόσθετο θεραπευτικό παράγοντα.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90322807P | 2007-02-23 | 2007-02-23 | |
US95871607P | 2007-07-06 | 2007-07-06 | |
EP08743531.9A EP2118082B1 (en) | 2007-02-23 | 2008-02-22 | Modulators of pharmacokinetic properties of therapeutics |
EP12167589.6A EP2487161B2 (en) | 2007-02-23 | 2008-02-22 | Modulators of pharmacokinetic properties of therapeutics |
PCT/US2008/054788 WO2008103949A1 (en) | 2007-02-23 | 2008-02-22 | Modulators of pharmacokinetic properties of therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122761T1 true CY1122761T1 (el) | 2020-11-25 |
Family
ID=39522375
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101075T CY1118292T1 (el) | 2007-02-23 | 2016-10-25 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY20161101152T CY1118219T1 (el) | 2007-02-23 | 2016-11-09 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101168T CY1118227T1 (el) | 2007-02-23 | 2016-11-14 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101170T CY1118232T1 (el) | 2007-02-23 | 2016-11-15 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017002C CY2017002I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017001C CY2017001I1 (el) | 2007-02-23 | 2017-01-04 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY2017003C CY2017003I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20201100220T CY1122761T1 (el) | 2007-02-23 | 2020-03-13 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2020011C CY2020011I2 (el) | 2007-02-23 | 2020-06-05 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101075T CY1118292T1 (el) | 2007-02-23 | 2016-10-25 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY20161101152T CY1118219T1 (el) | 2007-02-23 | 2016-11-09 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101168T CY1118227T1 (el) | 2007-02-23 | 2016-11-14 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101170T CY1118232T1 (el) | 2007-02-23 | 2016-11-15 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017002C CY2017002I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017001C CY2017001I1 (el) | 2007-02-23 | 2017-01-04 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY2017003C CY2017003I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2020011C CY2020011I2 (el) | 2007-02-23 | 2020-06-05 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
Country Status (32)
Country | Link |
---|---|
US (7) | US9891239B2 (el) |
EP (4) | EP3150586B1 (el) |
JP (9) | JP4881446B2 (el) |
KR (2) | KR101577698B1 (el) |
CN (2) | CN103435570B (el) |
AP (2) | AP2986A (el) |
AR (1) | AR065439A1 (el) |
AU (1) | AU2008218186C1 (el) |
BR (1) | BRPI0807581A2 (el) |
CA (1) | CA2678907C (el) |
CY (9) | CY1118292T1 (el) |
DK (2) | DK3150586T3 (el) |
EA (1) | EA019893B1 (el) |
ES (6) | ES2602784T3 (el) |
FI (1) | FI2487161T4 (el) |
FR (1) | FR20C1021I1 (el) |
HK (1) | HK1137451A1 (el) |
HR (5) | HRP20161371T1 (el) |
HU (6) | HUE029866T2 (el) |
IL (1) | IL200550A0 (el) |
LT (9) | LT2487163T (el) |
LU (1) | LUC00156I2 (el) |
MX (1) | MX2009008935A (el) |
NO (4) | NO2017003I1 (el) |
NZ (1) | NZ579802A (el) |
PL (3) | PL2487161T3 (el) |
PT (6) | PT3150586T (el) |
SG (2) | SG10201705929QA (el) |
SI (1) | SI3150586T1 (el) |
TW (1) | TWI533868B (el) |
WO (1) | WO2008103949A1 (el) |
ZA (1) | ZA200905882B (el) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1628685B1 (en) | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
ME01945B (me) * | 2004-07-27 | 2011-12-31 | Gilead Sciences Inc | Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a |
AP2985A (en) * | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
EP2465855A1 (en) * | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
ME02628B (me) | 2007-02-23 | 2017-06-20 | Gilead Sciences Inc | Modulatori farmakokinetičkih svojstava lekova |
ES2602784T3 (es) | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos |
EP2222324A2 (en) * | 2007-11-20 | 2010-09-01 | Concert Pharmaceuticals, Inc. | Boceprevir derivatives for the treatment of hcv infections |
EP2231628B1 (en) * | 2008-01-04 | 2015-10-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
CN104940937A (zh) | 2008-05-02 | 2015-09-30 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
PT2307435E (pt) * | 2008-07-08 | 2012-09-19 | Gilead Sciences Inc | Sais de compostos inibidores de vih |
PT2364314E (pt) | 2008-12-09 | 2014-06-09 | Gilead Sciences Inc | Moduladores de recetores toll-like |
AU2015200637C1 (en) * | 2009-02-06 | 2017-08-03 | Gilead Sciences, Inc. | Tablets for combination therapy |
US20100285122A1 (en) * | 2009-02-06 | 2010-11-11 | Gilead Sciences, Inc. | Tablets for combination therapy |
UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
WO2010151672A2 (en) * | 2009-06-26 | 2010-12-29 | Georgetown University | Amino acid derived ureas |
ES2969969T3 (es) | 2010-01-27 | 2024-05-23 | Viiv Healthcare Co | Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH |
NL2005306C2 (nl) * | 2010-09-02 | 2012-03-05 | Tersia Nederland B V | Koppelstuk voor meerlaagse leidingen, lasapparaaat voor het verbinden van het koppelstuk met meerlaagse leidingen, werkwijze van koppelen en een samenstel verkregen via de werkwijze. |
WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
RS53691B1 (en) * | 2010-11-19 | 2015-04-30 | Janssen R&D Ireland | THERAPEUTIC COMPOSITIONS CONTAINING RILPIVIRINE HCL AND TENOVOFIR DIZOPROXYL FUMARATE |
US8987313B2 (en) | 2010-12-21 | 2015-03-24 | Gilead Sciences, Inc. | Inhibitors of cytochrome P450 |
US20130274254A1 (en) | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
US20130280212A1 (en) * | 2010-12-21 | 2013-10-24 | Gilead Sciences, Inc | Inhibitors of cytochrome p450 |
EP2472320A2 (en) | 2010-12-30 | 2012-07-04 | Rohm and Haas Electronic Materials LLC | Compositions comprising base-reactive component and processes for photolithography |
EP2705027B1 (en) * | 2011-05-02 | 2015-06-03 | Gilead Sciences, Inc. | Amorphous solid salts of Cobicistat (GS-9350) |
BR112014000290B1 (pt) | 2011-07-07 | 2022-05-10 | Gilead Sciences, Inc. | Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir |
UY34262A (es) | 2011-08-16 | 2013-04-05 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos |
AU2012327170A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
RU2014129937A (ru) | 2012-02-03 | 2016-03-27 | Джилид Сайэнс, Инк. | Способы и промежуточные соединения для получения фармацевтических агентов |
KR20140119177A (ko) * | 2012-02-03 | 2014-10-08 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법 |
CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
WO2014057498A2 (en) | 2012-10-08 | 2014-04-17 | Mylan Laboratories Ltd. | Process for the preparation of cobicistat intermediates |
RU2648457C2 (ru) * | 2012-10-23 | 2018-03-26 | Сипла Лимитед | Фармацевтическая антиретровирусная композиция |
DK3608325T3 (da) | 2012-12-21 | 2022-08-22 | Gilead Sciences Inc | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse |
WO2014105777A1 (en) | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
NO2865735T3 (el) | 2013-07-12 | 2018-07-21 | ||
EP3019503B1 (en) | 2013-07-12 | 2017-09-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
PT3054926T (pt) | 2013-10-07 | 2018-10-26 | Bristol Myers Squibb Holdings Ireland | Formulação de atazanavir e cobicistat para tratamento de hiv |
ES2689654T3 (es) | 2013-12-03 | 2018-11-15 | Mylan Laboratories Ltd. | Preparación de productos intermedios de cobicistat |
WO2015145324A1 (en) | 2014-03-25 | 2015-10-01 | Mylan Laboratories Ltd | Process for the preparation of cobicistat |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
NO2717902T3 (el) | 2014-06-20 | 2018-06-23 | ||
EP4140485A1 (en) | 2014-07-11 | 2023-03-01 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
SG11201700341PA (en) * | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
SG11201701520TA (en) | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
SI3466490T1 (sl) | 2015-04-02 | 2020-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
CN107513046B (zh) * | 2016-06-15 | 2019-12-13 | 江苏欧信制药有限公司 | 一种可比司他的合成方法 |
AU2017305303B2 (en) * | 2016-08-04 | 2020-05-28 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
EP3496718A4 (en) | 2016-08-08 | 2020-01-22 | Hetero Labs Limited | ANTIRETROVIRAL COMPOSITIONS |
BR112019002120A2 (pt) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composição anti-retroviral de várias classes |
KR101908853B1 (ko) * | 2017-05-17 | 2018-10-16 | 경북대학교 산학협력단 | 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물 |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
CN109912530A (zh) * | 2017-12-13 | 2019-06-21 | 上海奥博生物医药技术有限公司 | 一种可比司他原料杂质的制备方法 |
CA3089388A1 (en) * | 2018-01-30 | 2019-08-08 | Sun Biopharma, Inc. | Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US191319A (en) * | 1877-05-29 | Improvement in stoves | ||
US108617A (en) * | 1870-10-25 | Improvement in ore-pulverizers | ||
US127689A (en) * | 1872-06-11 | Improvement in differential pulley-blocks | ||
US115665A (en) * | 1871-06-06 | Improvement in folding-steps for carriages | ||
US199851A (en) * | 1878-01-29 | Improvement in circular saws | ||
US77295A (en) * | 1868-04-28 | theqdoee krausch | ||
US143314A (en) * | 1873-09-30 | Improvement in condenser-tube fastenings | ||
US181902A (en) * | 1876-09-05 | Improvement in bell toys | ||
US99902A (en) * | 1870-02-15 | 1870-02-15 | Improvement in adjustable dials for travelers watches | |
US3400197A (en) | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
US3882114A (en) | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
GB1241024A (en) | 1968-10-29 | 1971-07-28 | Boehringer Sohn Ingelheim | Pharmaceutical tablet base and a process for its manufacture |
CA926708A (en) | 1970-06-15 | 1973-05-22 | Oushima Yoshitaka | Process for producing spherical pellets |
GB1339764A (en) | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
CH586568A5 (el) | 1972-04-10 | 1977-04-15 | Hoffmann La Roche | |
US3957774A (en) | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
DE2845326C2 (de) | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
US5142056A (en) | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
US4603143A (en) | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
GB8413191D0 (en) | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
FR2631620B1 (fr) | 1988-05-19 | 1990-07-27 | Rhone Poulenc Chimie | Nouvelle silice precipitee absorbante et composition a base de cette s ilice |
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
US5552558A (en) | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DE69332616T2 (de) | 1992-12-29 | 2003-11-06 | Abbott Lab | Hemmer der retroviralen Protease |
WO1995005808A1 (en) | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5763464A (en) | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
US6348216B1 (en) | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
JP4494539B2 (ja) | 1997-02-28 | 2010-06-30 | ディーエスエム アイピー アセッツ ビー.ブイ. | 流動自由な乾燥粒子 |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
FR2767071B1 (fr) | 1997-08-06 | 1999-09-10 | Rhodia Chimie Sa | Composition comprenant un liquide absorbe sur un support a base de silice precipitee |
WO1999033792A2 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
JP4027535B2 (ja) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
PT1733725E (pt) | 1999-06-04 | 2009-06-30 | Abbott Lab | Formulações farmacêuticas compreendendo pelo menos um composto inibidor da protease de hiv |
WO2001025240A1 (en) | 1999-10-06 | 2001-04-12 | Tibotec Pharmaceuticals Ltd. | HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
US6448245B1 (en) * | 2000-05-04 | 2002-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of and compounds for inhibiting calpains |
US20030035834A1 (en) | 2000-05-26 | 2003-02-20 | Pawan Seth | Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
KR20030040389A (ko) | 2000-09-19 | 2003-05-22 | 다이이찌 세이야꾸 가부시기가이샤 | 의약 조성물 |
US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
DE10112651A1 (de) | 2001-03-16 | 2002-09-19 | Degussa | Inhomogene Kieselsäuren als Trägermaterial |
PT1383482E (pt) | 2001-05-01 | 2007-09-20 | Pfizer Prod Inc | Método para o fabrico de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de fármaco uniforme |
DE10126163A1 (de) | 2001-05-30 | 2002-12-05 | Degussa | Pharmazeutische Zubereitungen |
ES2739023T3 (es) | 2001-07-06 | 2020-01-28 | Veloxis Pharmaceuticals As | Aglomeración controlada |
US7193065B2 (en) | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
US7815936B2 (en) | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
WO2003047551A1 (en) | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US7285566B2 (en) | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
JP4523281B2 (ja) | 2002-01-17 | 2010-08-11 | メルク・シャープ・エンド・ドーム・コーポレイション | Hivインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類 |
US6926906B2 (en) | 2002-02-20 | 2005-08-09 | M./S. Strides, Inc. | Orally administrable pharmaceutical formulation |
US6726448B2 (en) | 2002-05-15 | 2004-04-27 | General Electric Company | Ceramic turbine shroud |
PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
DE10250711A1 (de) | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmazeutische und kosmetische Zubereitungen |
MY136173A (en) | 2002-11-20 | 2008-08-29 | Japan Tobacco Inc | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
US7189416B2 (en) | 2002-11-23 | 2007-03-13 | Glykon Technologies Group, Llc | Method for stable and controlled delivery of (-)-hydroxycitric acid |
JP2004184681A (ja) | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
ATE398455T1 (de) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
US20060115524A1 (en) | 2003-02-19 | 2006-06-01 | H. Lundbeck A/S | Method for preparation of an agglomerate using melt agglomeration |
FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
JP4018664B2 (ja) | 2003-04-30 | 2007-12-05 | 第一三共株式会社 | 安定化固形製剤 |
DE10337198A1 (de) | 2003-08-13 | 2005-03-17 | Degussa Ag | Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
JP2005075826A (ja) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Internatl Gmbh | 多孔質シリカ担体を含有する徐放性製剤 |
JP2005091988A (ja) | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
WO2005032525A1 (en) | 2003-10-03 | 2005-04-14 | Lifecycle Pharma A/S | A method for preparing modified release pharmaceutical compositions |
US20050096390A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
US20050095287A1 (en) | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
US7834043B2 (en) | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
WO2005084670A1 (en) | 2004-03-01 | 2005-09-15 | Lek Pharmaceuticals D.D. | Pharmaceutical formulation |
MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
WO2005105040A2 (en) | 2004-04-26 | 2005-11-10 | Micelle Products, Inc. | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
JP2006003701A (ja) | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
EP1765297A2 (en) | 2004-06-28 | 2007-03-28 | LifeCycle Pharma A/S | Porous tablets as carriers for liquid formulations |
BRPI0512970A (pt) | 2004-07-06 | 2008-04-22 | Abbott Lab | prodrogas de inibidores da hiv protease |
AR045841A1 (es) | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
WO2006044968A2 (en) | 2004-10-19 | 2006-04-27 | Achillion Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
US20070014854A1 (en) | 2005-07-15 | 2007-01-18 | Ilan Zalit | Novel granulation process |
EP1978939A2 (en) | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
US20090233964A1 (en) | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
SG170796A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc Us | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
AU2007203715B2 (en) | 2006-01-05 | 2012-08-02 | Veloxis Pharmaceuticals A/S | Disintegrating loadable tablets |
WO2007097333A1 (ja) | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | 顆粒、錠剤およびそれらの製造方法 |
US20070287664A1 (en) | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
AP2985A (en) | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
WO2008017867A2 (en) | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition with at least one water insoluble polymer |
EP2465855A1 (en) | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
EP2063862A2 (en) | 2006-09-04 | 2009-06-03 | Matrix Laboratories Ltd | Pharmaceutical formulation for use in hiv therapy |
US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
ES2602784T3 (es) | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos |
CN101743004A (zh) * | 2007-06-29 | 2010-06-16 | 吉里德科学公司 | 治疗用组合物及其用途 |
BRPI0813000A2 (pt) * | 2007-06-29 | 2014-12-23 | Gilead Sciences Inc | Composições terapêuticas e uso das mesmas |
WO2009008989A1 (en) * | 2007-07-06 | 2009-01-15 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
DK2416157T3 (da) | 2007-12-27 | 2014-08-18 | Baxter Int | Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler |
CN104940937A (zh) * | 2008-05-02 | 2015-09-30 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
US20100285122A1 (en) | 2009-02-06 | 2010-11-11 | Gilead Sciences, Inc. | Tablets for combination therapy |
EP2238979A1 (en) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
JP6127981B2 (ja) | 2012-01-10 | 2017-05-17 | Jnc株式会社 | 発光層用材料およびこれを用いた有機電界発光素子 |
KR20140119177A (ko) | 2012-02-03 | 2014-10-08 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법 |
-
2008
- 2008-02-22 ES ES12167596.1T patent/ES2602784T3/es active Active
- 2008-02-22 AR ARP080100737A patent/AR065439A1/es not_active Application Discontinuation
- 2008-02-22 PT PT161805890T patent/PT3150586T/pt unknown
- 2008-02-22 DK DK16180589.0T patent/DK3150586T3/da active
- 2008-02-22 HU HUE12167596A patent/HUE029866T2/en unknown
- 2008-02-22 LT LTEP12167591.2T patent/LT2487163T/lt unknown
- 2008-02-22 ES ES12167591.2T patent/ES2603645T3/es active Active
- 2008-02-22 PL PL12167589T patent/PL2487161T3/pl unknown
- 2008-02-22 KR KR1020097019921A patent/KR101577698B1/ko active IP Right Grant
- 2008-02-22 US US12/528,185 patent/US9891239B2/en active Active
- 2008-02-22 HU HUE12167589A patent/HUE031707T2/en unknown
- 2008-02-22 PL PL12167590T patent/PL2487162T3/pl unknown
- 2008-02-22 ES ES08743531.9T patent/ES2525454T3/es active Active
- 2008-02-22 CA CA2678907A patent/CA2678907C/en active Active
- 2008-02-22 KR KR1020157011742A patent/KR101664154B1/ko active IP Right Grant
- 2008-02-22 AU AU2008218186A patent/AU2008218186C1/en active Active
- 2008-02-22 LT LTEP16180589.0T patent/LT3150586T/lt unknown
- 2008-02-22 US US12/036,124 patent/US8148374B2/en active Active
- 2008-02-22 NZ NZ579802A patent/NZ579802A/en unknown
- 2008-02-22 LT LTEP12167596.1T patent/LT2487166T/lt unknown
- 2008-02-22 HU HUE12167590A patent/HUE029842T2/en unknown
- 2008-02-22 FI FIEP12167589.6T patent/FI2487161T4/fi active
- 2008-02-22 EA EA200901155A patent/EA019893B1/ru unknown
- 2008-02-22 DK DK12167596.1T patent/DK2487166T3/en active
- 2008-02-22 EP EP16180589.0A patent/EP3150586B1/en active Active
- 2008-02-22 PL PL16180589T patent/PL3150586T3/pl unknown
- 2008-02-22 ES ES12167590.4T patent/ES2603617T3/es active Active
- 2008-02-22 WO PCT/US2008/054788 patent/WO2008103949A1/en active Application Filing
- 2008-02-22 LT LTEP12167589.6T patent/LT2487161T/lt unknown
- 2008-02-22 SI SI200832112T patent/SI3150586T1/sl unknown
- 2008-02-22 TW TW097106375A patent/TWI533868B/zh active
- 2008-02-22 CN CN201310326757.5A patent/CN103435570B/zh active Active
- 2008-02-22 LT LTEP12167590.4T patent/LT2487162T/lt unknown
- 2008-02-22 SG SG10201705929QA patent/SG10201705929QA/en unknown
- 2008-02-22 EP EP19219599.8A patent/EP3689353A1/en active Pending
- 2008-02-22 PT PT87435319T patent/PT2118082E/pt unknown
- 2008-02-22 PT PT121675904T patent/PT2487162T/pt unknown
- 2008-02-22 PT PT121675912T patent/PT2487163T/pt unknown
- 2008-02-22 SG SG2012054037A patent/SG183059A1/en unknown
- 2008-02-22 ES ES12167589.6T patent/ES2601820T3/es active Active
- 2008-02-22 BR BRPI0807581-6A2A patent/BRPI0807581A2/pt not_active Application Discontinuation
- 2008-02-22 PT PT121675961T patent/PT2487166T/pt unknown
- 2008-02-22 JP JP2009551044A patent/JP4881446B2/ja active Active
- 2008-02-22 EP EP12167589.6A patent/EP2487161B2/en active Active
- 2008-02-22 MX MX2009008935A patent/MX2009008935A/es active IP Right Grant
- 2008-02-22 EP EP08743531.9A patent/EP2118082B1/en active Active
- 2008-02-22 CN CN2008800132554A patent/CN101679325B/zh active Active
- 2008-02-22 PT PT121675896T patent/PT2487161T/pt unknown
- 2008-02-22 AP AP2009004964A patent/AP2986A/xx active
- 2008-02-22 AP AP2013007042A patent/AP3915A/en active
- 2008-02-22 ES ES16180589T patent/ES2779826T3/es active Active
- 2008-02-22 HU HUE12167591A patent/HUE029843T2/en unknown
-
2009
- 2009-08-23 IL IL200550A patent/IL200550A0/en unknown
- 2009-08-25 ZA ZA2009/05882A patent/ZA200905882B/en unknown
-
2010
- 2010-04-28 HK HK10104142.7A patent/HK1137451A1/xx unknown
-
2011
- 2011-08-23 JP JP2011181974A patent/JP5554300B2/ja active Active
- 2011-11-21 US US13/301,642 patent/US8486942B2/en active Active
-
2013
- 2013-07-03 US US13/935,117 patent/US20140017199A1/en not_active Abandoned
-
2014
- 2014-02-13 JP JP2014025059A patent/JP2014088441A/ja not_active Withdrawn
- 2014-11-04 US US14/532,868 patent/US20150139948A1/en not_active Abandoned
-
2015
- 2015-01-28 JP JP2015013971A patent/JP6147282B2/ja active Active
- 2015-08-03 US US14/817,068 patent/US20160069915A1/en not_active Abandoned
-
2016
- 2016-04-05 JP JP2016075593A patent/JP6147388B2/ja active Active
- 2016-07-05 JP JP2016132990A patent/JP6192776B2/ja active Active
- 2016-10-20 HR HRP20161371TT patent/HRP20161371T1/hr unknown
- 2016-10-25 CY CY20161101075T patent/CY1118292T1/el unknown
- 2016-11-01 US US15/340,538 patent/US20170158647A1/en not_active Abandoned
- 2016-11-02 HR HRP20161428TT patent/HRP20161428T1/hr unknown
- 2016-11-08 HR HRP20161476TT patent/HRP20161476T1/hr unknown
- 2016-11-09 CY CY20161101152T patent/CY1118219T1/el unknown
- 2016-11-14 HR HRP20161502TT patent/HRP20161502T1/hr unknown
- 2016-11-14 CY CY20161101168T patent/CY1118227T1/el unknown
- 2016-11-15 CY CY20161101170T patent/CY1118232T1/el unknown
- 2016-12-12 HU HUS1600054C patent/HUS1600054I1/hu unknown
- 2016-12-16 LT LTPA2016038C patent/LTC2487166I2/lt unknown
- 2016-12-16 LT LTPA2016039C patent/LTC2487163I2/lt unknown
- 2016-12-16 LT LTPA2016040C patent/LTC2487162I2/lt unknown
-
2017
- 2017-01-04 CY CY2017002C patent/CY2017002I2/el unknown
- 2017-01-04 CY CY2017001C patent/CY2017001I1/el unknown
- 2017-01-04 CY CY2017003C patent/CY2017003I2/el unknown
- 2017-01-12 NO NO2017003C patent/NO2017003I1/no unknown
- 2017-01-12 NO NO2017002C patent/NO2017002I1/no unknown
- 2017-01-12 NO NO2017001C patent/NO2017001I1/no unknown
- 2017-07-11 JP JP2017135437A patent/JP2017171695A/ja not_active Withdrawn
-
2019
- 2019-01-17 JP JP2019006234A patent/JP2019059790A/ja not_active Withdrawn
-
2020
- 2020-03-02 HR HRP20200349TT patent/HRP20200349T1/hr unknown
- 2020-03-13 CY CY20201100220T patent/CY1122761T1/el unknown
- 2020-06-02 LU LU00156C patent/LUC00156I2/en unknown
- 2020-06-03 HU HUS2000013C patent/HUS2000013I1/hu unknown
- 2020-06-04 LT LTPA2020508C patent/LTC3150586I2/lt unknown
- 2020-06-05 NO NO2020011C patent/NO2020011I1/no unknown
- 2020-06-05 CY CY2020011C patent/CY2020011I2/el unknown
- 2020-06-17 FR FR20C1021C patent/FR20C1021I1/fr active Active
- 2020-10-08 JP JP2020170304A patent/JP2021001236A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122761T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
CY1116688T1 (el) | Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων | |
EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
CY1119176T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
CY1119177T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων | |
CY1120796T1 (el) | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων | |
CY1115176T1 (el) | Ρυθμιστες υποδοχεων τυπου toll | |
CY1119547T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι χρησιμες για κινητοποιηση χοληστερολης | |
CY1119488T1 (el) | Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου | |
CY1113352T1 (el) | Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους | |
PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
HN2009003002A (es) | Compuestos de piridopirimidinonas inhibidores de pi3k-alfa | |
BRPI0821255A2 (pt) | Derivados de espiroindolinona | |
CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
TW200806291A (en) | Pharmaceutical formulations | |
CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
UA101312C2 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов | |
CY1115013T1 (el) | Διαμορφωτες υποδοχεα 7 που προσομοιαζει toll | |
EA200901085A1 (ru) | Производные циклогексиламида арилкарбоновой кислоты | |
UA97112C2 (ru) | Модуляторы фармакокинетических свойств лекарственных средств |